India, Jan, 2026 – Quintile Reports, a premier source for healthcare industry research and strategic insights, has unveiled its newest market report on the Minimal Residual Disease Testing market. This detailed study examines the market’s growth trajectory, key players, and innovations driving adoption in oncology diagnostics. With MRD testing gaining prominence in improving prognosis and treatment monitoring, the report offers crucial data for stakeholders navigating this high-impact segment.
The report highlights how minimal residual disease (MRD) testing is transforming cancer diagnostics and treatment monitoring, particularly in hematological malignancies such as leukemia, lymphoma, and multiple myeloma. MRD testing technologies such as flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS) are enabling clinicians to detect microscopic disease levels with high precision. These advancements are supporting oncologists, diagnostic laboratories, and research institutions in making informed treatment decisions, assessing relapse risk, and improving patient outcomes.
The global minimal residual disease testing market is projected to grow at a compound annual growth rate (CAGR) of 10.80% between 2025 and 2035. Key growth drivers include rising cases of blood cancers, increasing demand for early relapse detection, and the growing adoption of personalized medicine. Advances in NGS, flow cytometry, and digital PCR are enhancing test accuracy, while supportive regulations and broader reimbursement are fueling market expansion.
The report provides a detailed analysis of the competitive environment, profiling major companies such as Guardant Health, Natera Inc., Adaptive Biotechnologies, Invitae Corporation, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., LabCorp (Laboratory Corporation of America), Quest Diagnostics, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen N.V., Eurofins Scientific, Genomic Health (Exact Sciences), Sysmex Corporation, Becton Dickinson and Company. These players are at the forefront of MRD testing innovation, investing in advanced molecular diagnostics, next-generation sequencing technologies, strategic collaborations, and clinical validation efforts to expand their market presence and enhance precision oncology solutions.
Recent developments include Medicare coverage secured by Natera Inc. for its Signatera MRD assay in ovarian and neoadjuvant breast cancer, and a strategic partnership between Bio-Rad Laboratories and Allegheny Health Network to validate ddPCR-based MRD assays in solid tumors. These advancements reflect growing clinical validation efforts and strategic collaborations driving innovation in the MRD testing market.
The MRD testing market faces challenges such as limited payer coverage, high test costs, and infrastructure barriers, particularly in low-resource settings. Advanced platforms like NGS and digital PCR require significant investment, skilled personnel, and validated bioinformatics pipelines, making widespread implementation difficult. The lack of global standardization in testing protocols and reporting methods hinders data comparability and clinical decision-making. Furthermore, biological complexities such as low ctDNA levels and interference from non-tumor DNA limit the effectiveness of MRD testing in solid tumors. Addressing these multifaceted issues is essential to realizing the full clinical and commercial potential of MRD testing.
The future of MRD testing looks highly promising, fueled by rising adoption of precision oncology, increasing use in clinical trials, and ongoing advancements in molecular diagnostics. Quintile Reports recommends that stakeholders focus on improving affordability, expanding reimbursement coverage, and investing in standardized testing protocols to support broader clinical integration.
MRD solutions that offer high sensitivity, streamlined workflows, and validated clinical utility will be best positioned for sustained growth. Emerging players are expected to target cost-effective platforms, solid tumor applications, and scalable solutions for developing regions to address unmet diagnostic needs.
Quintile Reports, a part of Quintile Group, is a global market intelligence firm delivering actionable insights across industries including MedTech, Pharmaceuticals, Biotechnology, Consumer Goods, Automotive, Agriculture, Aerospace & Defense, Semiconductors, Energy & Power and Financial Services. With expert analysts and a presence across the U.S., UK, and APAC, we help businesses navigate market complexities, identify growth opportunities, and make informed decisions. At Quintile Reports, we turn data into strategy—fueling innovation through trusted research and secure, in-depth analysis.
Sarah Singh (Chief Strategic Marketing)
Quintile Reports
Email: sales@quintilereports.com
India, Jan, 2026 – Quintile Reports, a premier source for healthcare industry research and strategic insights, has unveiled its newest market report on the Minimal Residual Disease Testing market. This detailed study examines the market’s growth trajectory, key players, and innovations driving adoption in oncology diagnostics. With MRD testing gaining prominence in improving prognosis and treatment monitoring, the report offers crucial data for stakeholders navigating this high-impact segment.
The report highlights how minimal residual disease (MRD) testing is transforming cancer diagnostics and treatment monitoring, particularly in hematological malignancies such as leukemia, lymphoma, and multiple myeloma. MRD testing technologies such as flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS) are enabling clinicians to detect microscopic disease levels with high precision. These advancements are supporting oncologists, diagnostic laboratories, and research institutions in making informed treatment decisions, assessing relapse risk, and improving patient outcomes.
The global minimal residual disease testing market is projected to grow at a compound annual growth rate (CAGR) of 10.80% between 2025 and 2035. Key growth drivers include rising cases of blood cancers, increasing demand for early relapse detection, and the growing adoption of personalized medicine. Advances in NGS, flow cytometry, and digital PCR are enhancing test accuracy, while supportive regulations and broader reimbursement are fueling market expansion.
The report provides a detailed analysis of the competitive environment, profiling major companies such as Guardant Health, Natera Inc., Adaptive Biotechnologies, Invitae Corporation, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., LabCorp (Laboratory Corporation of America), Quest Diagnostics, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen N.V., Eurofins Scientific, Genomic Health (Exact Sciences), Sysmex Corporation, Becton Dickinson and Company. These players are at the forefront of MRD testing innovation, investing in advanced molecular diagnostics, next-generation sequencing technologies, strategic collaborations, and clinical validation efforts to expand their market presence and enhance precision oncology solutions.
Recent developments include Medicare coverage secured by Natera Inc. for its Signatera MRD assay in ovarian and neoadjuvant breast cancer, and a strategic partnership between Bio-Rad Laboratories and Allegheny Health Network to validate ddPCR-based MRD assays in solid tumors. These advancements reflect growing clinical validation efforts and strategic collaborations driving innovation in the MRD testing market.
The MRD testing market faces challenges such as limited payer coverage, high test costs, and infrastructure barriers, particularly in low-resource settings. Advanced platforms like NGS and digital PCR require significant investment, skilled personnel, and validated bioinformatics pipelines, making widespread implementation difficult. The lack of global standardization in testing protocols and reporting methods hinders data comparability and clinical decision-making. Furthermore, biological complexities such as low ctDNA levels and interference from non-tumor DNA limit the effectiveness of MRD testing in solid tumors. Addressing these multifaceted issues is essential to realizing the full clinical and commercial potential of MRD testing.
The future of MRD testing looks highly promising, fueled by rising adoption of precision oncology, increasing use in clinical trials, and ongoing advancements in molecular diagnostics. Quintile Reports recommends that stakeholders focus on improving affordability, expanding reimbursement coverage, and investing in standardized testing protocols to support broader clinical integration.
MRD solutions that offer high sensitivity, streamlined workflows, and validated clinical utility will be best positioned for sustained growth. Emerging players are expected to target cost-effective platforms, solid tumor applications, and scalable solutions for developing regions to address unmet diagnostic needs.
Quintile Reports, a part of Quintile Group, is a global market intelligence firm delivering actionable insights across industries including MedTech, Pharmaceuticals, Biotechnology, Consumer Goods, Automotive, Agriculture, Aerospace & Defense, Semiconductors, Energy & Power and Financial Services. With expert analysts and a presence across the U.S., UK, and APAC, we help businesses navigate market complexities, identify growth opportunities, and make informed decisions. At Quintile Reports, we turn data into strategy—fueling innovation through trusted research and secure, in-depth analysis.
Sarah Singh (Chief Strategic Marketing)
Quintile Reports
Email: sales@quintilereports.com
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Immediate / Within 24-48 hours - Working days
Online Payments with PayPal and CCavenue
You can order a report by picking any of the payment methods which is bank wire or online payment through any Debit/Credit card or PayPal.
Hard Copy
U.S. : +1-201-772-7734